Preview of New MedDRA Hierarchy for Medication Errors Coding and Retrieval Considerations

Similar documents
Data retrieval using the new SMQ Medication Errors

MedDRA Term Selection: Latest activities of the Points to Consider Working Group

Use of MedDRA in Special Situations

Frequently Asked Questions

MedDRA Coding Quality: How to Avoid Common Pitfalls

What s New MedDRA Version March

GDUFA: 2 ½ years later Impact & Importance

MedDRA Basic Concept

Other EU Activities Contributing to Harmonization of Labeling

Medication Errors a challenge of pharmacovigilance BfArM experience

MedDRA Overview A Standardized Terminology

Healthcare Professional Information & Patient Information Leaflet (PL)

Session 2. Data analysis based on overview of EudraVigilance data. Victoria Newbould, EMA, EU. Medication-errors workshop London, 20 October 2016

Advanced MedDRA Coding

Disclaimer. Statistical Aspects of Revision of CHMP Bioequivalence Guidelines. David Brown MHRA

Global Pediatric Development: We Are Making Progress. PMDA Perspective. Junko Sato, PhD PMDA

Life-cycle approach to error prevention an overview

Overview of the MedDRA Data Retrieval and Presentation: Points to Consider Document including Standardised MedDRA Queries (SMQs)

9/20/2011. Impact of EU Paediatric Regulation on drug development and Marketing authorisations Industry experience

MedDRA TERM SELECTION: POINTS TO CONSIDER

What s New MedDRA Version 18.0

Centralized Procedure

Medication errors. Impact of medication error guidance and regulation on drug-device combination products. June 2017 Dan Wozinski

Disclaimer. Dialogue with a Patient 3/18/2016

Web-based epro: Validation, Equivalence, and Data Quality. Brian Tiplady

PMDA Perspectives on Oncology Panel. REIKO YANAGIHARA, Ph.D. Office of In Vitro Diagnostics PMDA

Proposed MedDRA Version 17.0 Complex Changes (July 2013)

So, My FitBit is Clinical Trial Grade Right? Keith Wenzel Senior Director, Solution Incubator PAREXEL International

Regulatory scientific significance of Japan s ADR relief system

Implemented MedDRA Version 22.0 Complex Changes (October 2018)

MedDRA TERM SELECTION: POINTS TO CONSIDER

What s New MedDRA Version MSSO-DI March 2016

MedDRA Coding and Versioning

Data Analysis and Query Building with MedDRA

Disclaimer. The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be

Coding with MedDRA 3/2/2017

Regulatory Experience in Reviewing CV Safety for Diabetes

3/31/2009. Phase 0 Microdosing Studies with Renin Inhibitors. Disclaimer. Overview of Today s Presentation. J. Chris Jensen Consultant

MedDRA 13.0 Review. General Remarks. Version 13.0 Changes Overview. Changes in a Nutshell. Changes Highlights. MedDRA Version Changes

What s New MedDRA Version March

PHARMACOVIGILANCE GLOSSARY

What Medical Writers Need to Know About MedDRA

Data Analysis and Query Building with MedDRA

Coding with MedDRA 1

Existing WHO work on Medicines Safety & Safe Use. Department of Essential Medicines and Health Products World Health Organization

Testing Railway Safety Critical Workers for Drugs and Alcohol

Coding with MedDRA 4/22/2015

MedDRA 14.0 Review MedDRA Version Changes General Remarks MedDRA Version 14.0 Specific Changes Version 14.0 Changes Overview Changes in a Nutshell

Coding with MedDRA 3/6/2019

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER

Quality, Safety and Sourcing in Unlicensed Medicines

MedDRA TERM SELECTION: POINTS TO CONSIDER

Conducting Observational studies in Latin America: Academia, Ethical Committees & Pharmaceutic Industry

Coding with MedDRA 1

The Adverse Reactions and Interactions

Regulatory Aspects - AML & CLL

The European Medicines Agency (EMA)

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER

Pharmacovigilance Methods and Post-Authorisation Safety Studies

MedDRA - International standard for coding safety information. The Golden Triangle

MedDRA 10.1 Review. MedDRA Version 10.1 What s coming ahead? MedDRA Version Changes. General Remarks. Terminology Files: What you need to know

Workshop Medication Errors

USE OF UNLICENSED MEDICINES AND OFF-LABEL MEDICINES WHERE A LICENSED MEDICINE IS AVAILABLE

Coding with MedDRA. MedDRA trademark is owned by IFPMA on behalf of ICH

Coding with MedDRA. of the MedDRA Maintenance and Support Services Organization (MSSO) are overseen by an ICH MedDRA

Understand Medication and Prescriptions

Frequently asked questions

Changing practice to support service delivery

The Telemetric and Holter ECG Warehouse (THEW) Initiative

Safety Data Analysis and Query Creation with MedDRA

What s New MedDRA Version 13.1

PIP Modifications Workshop. Co-Chairs

Testing Railway Safety Critical Workers for Drugs and Alcohol

Coding with Confidence

Food can serve as a non pharmacological control in thorough cardiac safety studies

SUPPLEMENTAL NOTE ON HOUSE BILL NO. 2217

Navigating the Table of Drugs & Chemicals

concentrate intravenous solution and other strong potassium solutions

10/27/2011. Challenges in Anti-diabetic Global Drug Development A Shift from Surrogate to Outcome Trials. Disclaimer

DIA Oligonucleotide-Based Therapeutics Conference

MedDRA TERM SELECTION: POINTS TO CONSIDER

What s New MedDRA Version 15.1

Introduction to MedDRA

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER

PGEU GPUE. Pharmaceutical Group of European Union Groupement Pharmaceutique de l Union Européenne

Electrocardiographic Markers Associated with Sotalol-induced Torsades de Pointes

Provider Education & Utilization Initiatives Alliance of States with PMPs East Regional Meeting

Routine signal detection and statistical tools on paediatrics

Asthma Foundation NSW Centre Support

What s New MedDRA Version 14.0

The Role of the Responsible Pharmacist (RP)

Applies to: Signal and Incident Management Service in the Inspections, Human Medicines Pharmacovigilance and Committees division

Guidelines on the Sourcing of Medicinal Products for Sale or Supply by a Retail Pharmacy Business

Naloxone Expanded Access: OTC status Considerations for a Nonprescription Drug Development Program

Draft Guidelines on the Sale and Supply of Non- Prescription Medicinal Products from a Retail Pharmacy Business

quality and safety of pharmacy preparations in Europe

6/7/2017 CHANGES IN PHARMA REGULATIONS HOW IT AFFECTS THE OR NURSE DISCLOSURE OBJECTIVES

Risk analysis for veterinary vaccines in Australia

40 Use and Supply of Drugs or Medicines in Optometric Practice

Farmakovijilans ve MedDRA Pharmacovigilance and MedDRA FARMAKOVİJİLANS ve FARMAKOVİJİLANS UYGULAMALARI EKİM Dr.

Transcription:

Preview of New MedDRA Hierarchy for Medication Errors Coding and Retrieval Considerations Judy Harrison, M.D. Chief Medical Officer MedDRA MSSO Information Day on Medication Errors 20 October 2016 London, UK

Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. ( DIA ), its directors, officers, employees, volunteers, members, chapters, councils, Special Interest Area Communities or affiliates, or any organisation with which the presenter is employed or affiliated. These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. Drug Information Association, DIA and DIA logo are registered trademarks or trademarks of Drug Information Association Inc. All other trademarks are the property of their respective owners. 2

Outline Background to hierarchy revision Overview of new hierarchy Impact on coding medication errors Retrieval considerations 3

EU Pharmacovigilance Directive Recital 17 Member States should operate a pharmacovigilance system to collect information that is useful for the monitoring of medicinal products, including information on suspected adverse reactions arising from use of a medicinal product within the terms of the marketing authorisation as well as from use outside the terms of the marketing authorisation, including overdose, misuse, abuse and medication errors, and suspected adverse reactions associated with occupational exposure. 4

Previous Revision Revised March 2015 MedDRA Version 18.0 Hierarchy helps Medication errors, misuse, off label use, overdoses, underdoses in same SOC Miscellaneous product use issues Intentional Neutral/unspecified 5 MedDRA Version 19.0

Previous Revision (cont) Overlapping concepts Hierarchy hinders Forces distinction between MEs and product use issues, but Some terms in HLGT Medication errors don t specify error or accidental Neutral terms in HLT Product use issues NEC that could represent medication errors, misuse, or off label use e.g., PT Drug administered to patient of inappropriate age Google Images 6

New Hierarchy Discussed with expert groups Points to Consider Working Group MedDRA Expert Panel Posted complex change proposal for comments from MedDRA users (July-September 2016) Majority of feedback in favour To be implemented in MedDRA Version 20.0 (March 2017) 7

Advantages Avoids force-classification of MEs vs. product use Classification by stage in the medication/product process (EMA Good Practice Guide Section 5.5.1) Intercepted medication errors under relevant stage HLTs Intentional concepts separated from errors/unspecified issues Product covers medication and other product concepts such as device use/error terms 8

Preview of New Hierarchy HLGT Medication errors and other product use errors and issues Accidental exposures to product Medication errors, product use errors and issues NEC Product administration errors and issues Product confusion errors and issues Product dispensing errors and issues Product monitoring errors and issues Product preparation errors and issues Product prescribing errors and issues Product selection errors and issues Product storage errors and issues in the product use system Product transcribing errors and communication issues Existing grouping term New grouping term 9

Preview of New Hierarchy (cont) HLGT Off label uses and intentional product misuses/use issues Off label uses Intentional product misuses Intentional product use issues HLGT Overdoses and underdoses NEC Overdoses NEC Underdoses NEC Existing grouping term New grouping term 10

Coding Principles Select LLT that that most accurately reflects the reported verbatim information Refer to concept descriptions in MedDRA Introductory Guide May be appropriate to select more than one term Familiarity with hierarchy is essential Navigating Top down is optimal approach for medication errors and product use issues Check hierarchy to ensure placement reflects meaning MedDRA Term Selection: Points to Consider document 11

Coding Example 1 Due to a prescribing error, the child was given drug X which is labelled for use in adults only LLT PT HLT HLGT Current hierarchy (MedDRA v19.0) New hierarchy Stages of error represented Terms in same HLGT Drug prescribing error Drug prescribing error Medication errors NEC Adult product administered to child Drug administered to patient of inappropriate age Product use issues NEC Drug prescribing error Drug prescribing error Product prescribing errors and issues Adult product administered to child Drug administered to patient of inappropriate age Product administration errors and issues Medication errors Product use issues Medication errors and other product use errors and issues Medication errors and other product use errors and issues 12

Coding Example 2 Pharmacist inadvertently dispensed the wrong size syringe. Patient gave himself insulin with the syringe. LLT PT HLT HLGT Current hierarchy (MedDRA v19.0) Wrong device dispensed Drug administered in wrong device Wrong device dispensed Device issues NEC Device issues (SOC product issues) Drug administered in wrong device Maladministrations Medication errors New hierarchy Stages of error represented Product covers devices Terms in same HLGT and SOC Wrong device dispensed Drug administered in wrong device Wrong device dispensed Drug administered in wrong device Product dispensing errors and issues Product administration errors and issues Medication errors and other product use errors and issues Medication errors and other product use errors and issues 13

Retrieval Considerations New HLGT combines medication (product) errors and unspecified use issues Advantage: Retrieve true errors and use issues often associated with MEs Disadvantage: May be noisy if want to retrieve only true MEs Other terms that aren t specifically MEs but have potential to identify MEs because of frequent association Product quality issues Device issues, e.g., malfunctions Exposures Compliance issues Hierarchy alone is not sufficient to retrieve potential cases 14

Hierarchy vs. Hashtag Different retrieval approach Hashtag (#) Label used on social media to identify specific topics Similar concept can be applied to MedDRA data Tag terms representing potential MEs independent of vertical hierarchy SMQ Medication errors Twitter 15

Tagging Medication Errors in E2B(R3) New code list available in E2B (R3) when implemented G.k.10.r Additional information on drug (coded) Counterfeit Overdose Drug taken by the father Drug taken beyond expiry date Batch and lot tested and found within specifications Batch and lot tested and found not within specifications Medication error Misuse Abuse Occupational exposure Off label use Clear method of classification and identification 16

Summary New hierarchy to be implemented in March 2017 Addresses issues identified by users Supports regulatory requirements for coding and reporting medication errors 17

Ask